slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 224,281-224,310
Pages 10,126
Rows per page 30
Component
224,281-224,310 of 303,780
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes patient case study with longitudinal MRI scans.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
38
The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
43
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
47
The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
48
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-style visualization to represent clinical trial progress.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
04
The diagram uses a circular process flow (Assess, Prescribe, Dispense, Administer) surrounding a central 'One Platform' core.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a numbered process-style layout to present four distinct strategic advantages.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a stepped maturity model framework to show the evolution from manual to fully autonomous pharmacy operations.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · SolutionLoop · Analogy1 hit
07
The slide uses a semi-circular layout to map specific service offerings to different care environments.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · SolutionLoop · Analogy1 hit
08
The chart uses a central circle to display the total TAM, with segments radiating outward.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Market Size1 hit
09
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
10
The slide highlights the shift toward recurring revenue models through cloud-based services.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
11
The slide uses a before-after framing to justify a shift in business model strategy.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit